APA (7th ed.) Citation

Sagara, R., Ishigaki, M., Otsuka, M., Murayama, K., Ida, H., & Fernandez, J. (2021). Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan. BMC.

Chicago Style (17th ed.) Citation

Sagara, Rieko, Masahide Ishigaki, Manami Otsuka, Kei Murayama, Hiroyuki Ida, and Jovelle Fernandez. Long-term Safety and Effectiveness of Velaglucerase Alfa in Gaucher Disease: 6-year Interim Analysis of a Post-marketing Surveillance in Japan. BMC, 2021.

MLA (8th ed.) Citation

Sagara, Rieko, et al. Long-term Safety and Effectiveness of Velaglucerase Alfa in Gaucher Disease: 6-year Interim Analysis of a Post-marketing Surveillance in Japan. BMC, 2021.